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ABSTRACT  
Building on an initiative to enhance clinical trial participation involving the Society for Neuro-
Oncology (SNO), the Response Assessment in Neuro-Oncology (RANO) Working Group, patient 
advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of 
eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often 
carry forward eligibility criteria from prior studies that may be overly restrictive, unnecessary, and 
needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the 
goals and design of the study and whether they impact patient safety and/or treatment efficacy. In 
addition, we evaluate clinical trial conduct as barriers to accrual and discuss strategies to minimize 
such barriers for neuro-oncology trials.  
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INTRODUCTION 
It is estimated that only 21% of patients with primary brain tumors and only 8-11% of newly 
diagnosed glioblastoma (GBM) patients participate in clinical trials1,2 even though there is limited 
therapeutic benefit associated with available standard therapies and there are several promising 
investigational approaches under evaluation in clinical trials. Although the etiology of poor accrual is 
likely multifactorial3, failure to incorporate optimal eligibility criteria is a contributing factor. Despite 
the increasing sophistication of clinical trial designs, eligibility criteria for these trials are often overly 
burdensome and restrictive. The intent of eligibility criteria is to protect patients from harm and to 
identify a well-defined population to effectively address the key questions of a given trial. Often 
eligibility criteria are included “out of habit” or copied from prior protocols without re-evaluating the 
continuing value of each individual inclusion or exclusion criterion relative to the key questions of the 
study. Consequently, patients may be deemed ineligible for reasons that do not directly impact safety 
or efficacy.  
 
When brain tumor patients and caregivers were asked about barriers to clinical trial participation in a 
recent National Brain Tumor Society survey, “I did not qualify” was the second most common reason, 
after “my doctor did not recommend participating in a clinical trial”.1 Clearly physicians caring for 
brain tumor patients need to prioritize presentation of clinical trial options, but failure to qualify 
underscores the critical need to carefully optimize eligibility criteria on a trial by trial basis in order to 
ensure as many patients as possible can participate. The reasons for ineligibility vary depending on the 
clinical trial and are difficult to capture. We attempted to examine the reasons for ineligibility at an 
academic institution with high referral basis for clinical trials. However, our analysis was limited to 
those patients who signed consent but ultimately did not enroll on study (i.e., screen failures). As some 
clinical trial providers “pre-screen” potential participants for trial eligibility before offering those 
trials, some patients who did not meet criteria never signed consent for a trial and their reasons for 
exclusion were not documented. Based on patients with newly diagnosed or recurrent GBM who 
signed consent and were screened for one of six principal investigator initiated clinical trials at Dana-
Farber Cancer Institute between 3/2009 and 2/2019 but ultimately did not enroll on the study, 
Eligibility Criteria (N-O-D-19-00853R1) – page 7 
 
ineligibility was due to a variety of reasons, including incorrect histopathology [i.e., not World Health 
Organization (WHO) grade IV], insufficient tissue for correlative studies, and laboratory abnormalities 
(Figure 1). Although further prospective studies are needed to more clearly document the reasons for 
ineligibility in brain tumor clinical trials, the neuro-oncologic academic community can and should 
move toward more deliberate examination of eligibility criteria.  
 
The American Society for Clinical Oncology (ASCO) and the Friends of Cancer Research (Friends) 
recently led an effort to optimize oncology trial eligibility in 5 specific areas: brain metastases4, 
minimum age5, HIV infection6, organ dysfunction, and prior and concurrent malignancies7. They 
recognized that overly restrictive eligibility criteria slow trial accrual, restrict patient access to 
investigational drugs, reduce the chances of knowing how the drug will work in the real world (i.e., 
limit generalizability), and result in duplicative efforts with respect to drug development.8 Based on 
this ASCO/Friends initiative, the United States (US) Food and Drug Administration (FDA)9-12 issued 
new draft guidance documents for inclusion and exclusion criteria with respect to these 5 specific 
areas and the National Cancer Institute (NCI)13 amended protocol templates to reflect some of these 
changes. Building on this work, the Society for Neuro-Oncology (SNO); the Response Assessment in 
Neuro-Oncology (RANO) Working Group; patient advocacy groups; clinical trial cooperative groups 
including the Adult Brain Tumor Consortium (ABTC), the Brain Tumor Committee of NRG 
Oncology, the Neuro-Oncology Committee for the Alliance for Clinical Trials in Oncology, and the 
European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group; and 
other partners have joined efforts to increase clinical trial accrual to neuro-oncology trials.3 Here, we 
evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation 
(Table 1). The recommendations that follow represent consensus guidelines based on evidence (when 
available) and expert opinion. They are meant to provide a framework for critically evaluating 
eligibility criteria and conduct in current day neuro-oncology trials. As our understanding of brain 
tumors evolve, trial design including eligibility criteria will similarly need to evolve beyond what is 
discussed here. We also note that the desire to increase clinical trial participation must also be 
balanced with the ability to answer a scientific question, which may sometimes warrant restricting 
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eligibility, such as limiting participation to the appropriate molecular subgroup for targeted therapy. 
Finally, critical evaluation of eligibility criteria and clinical trial conduct will be for naught if we do 
not increase the number of high-quality, thoughtful clinical trials (a topic outside the scope of this 
paper).  
 
GENERAL ELIGIBILITY CRITERIA 
Patient Factors 
Patient factors that form the basis for eligibility criteria across neuro-oncology trials include age, 
functional status, past medical history, and prior therapies. Adult trials typically restrict enrollment to 
age 18 and older. ASCO/Friends5 and the FDA9 provide guidance on when to allow children as young 
as age 12 to participate in adult cancer trials. This is particularly relevant in tumor subtypes where the 
disease biology and clinical course is similar in children and adults, such as H3K27M mutant diffuse 
midline glioma14, or when an adult disease rarely presents in adolescents15. At the other end of the age 
spectrum, older patients (age ≥ 65) are not well represented in clinical trials.16,17 Indeed, the phase III 
trial which established radiation and temozolomide as standard of care for newly diagnosed GBM 
excluded patients above the age of 70.18 Since the median age at GBM diagnosis in the US is 65 
years19, excluding older patients leads to a lack of data for an important portion of the GBM 
population. Even when not explicitly excluded by age, patients can be excluded by co-morbidities or 
concomitant medications. The FDA provides a guidance document to promote inclusion of elderly 
patients on trials when the drugs are likely to be used in the elderly.17  
 
Historically, patients with a prior malignancy have been excluded from clinical trials with a few 
exceptions. When the risk of the prior malignancy interfering with the trials end points or safety is 
deemed to be low, participation should be allowed. We agree with the ASCO/Friends recommendation 
to allow participation of patients with a prior or concurrent history of malignancy whose natural 
history or treatment does not have the potential to interfere with the safety or efficacy assessment of 
the investigational regimen.20  
 
Eligibility Criteria (N-O-D-19-00853R1) – page 9 
 
Requirements for overly long washout periods of previous drug treatments may also interfere with 
study enrollment. If the goal is to eliminate the carry-over effects from the prior treatment to avoid 
overlapping toxicities, then the often applied 4-week washout period from prior investigational agents 
is often excessive. Instead, a washout period of 5 times the half-life of the prior treatment may suffice 
for cytotoxic chemotherapies or targeted therapies. Even so, this may be unnecessarily long for 
treatments with long half-lives such as bevacizumab or checkpoint inhibitors. A general statement that 
the patient must have recovered from the anticipated effects of prior treatment would allow for even 
broader participation.  
 
Archival Tissue Requirements 
Some clinical trials mandate central review of the tumor as well as molecular testing (e.g., MGMT 
promotor methylation status or genotyping), which may be redundant when similar data from Clinical 
Laboratory Improvement Amendments (CLIA) certified laboratories or the equivalent are available. In 
these situations, the demand for large amount of tissues, and more specifically frozen tissue, will 
severely hamper accrual. The amount and type of tissue required for study enrollment needs a strong 
rationale and should be limited to only what is absolutely necessary to assess the study’s key 
questions. Of note, advances in tissue-based testing are resulting in large reductions in the amount of 
tumor required for even advanced molecular analyses, which can usually be performed on formalin-
fixed material. 
 
Molecular Subtypes for Targeted Therapy Trials 
Genomic data for trial eligibility is often derived from the initial sample. While this is reasonable for 
genomic alterations that are generally stable across recurrences [such as isocitrate dehydrogenase 
(IDH) mutational status], gliomas can harbor new molecular changes at recurrences21. For example, 
37% of EGFRvIII mutations are lost at tumor recurrence.21 Therefore, depending on the target, a 
repeat biopsy should be considered to confirm target expression prior to participation on a molecularly 
driven trial.   
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Laboratory Values and Organ Dysfunction 
Specifying parameters for laboratory values and organ function is critical for patient safety and to 
ensure that the study can be completed without excessive treatment modification or discontinuations 
based on poor tolerance and toxicity. Overly stringent requirements without an allowance for a safe 
range above normal parameters can limit enrollment, particularly for patients with advanced disease. 
We agree with recommendations from Friends/ASCO regarding increased inclusiveness of patients 
with organ dysfunction, including renal, hepatic, and cardiac dysfunction when appropriate.20 Only the 
relevant laboratory tests and cardiac status based on the safety profile of the study agent should be 
used as the basis for eligibility criteria (Table 2). 
 
Immunotherapy Trials  
Although effective immunotherapy remains elusive for the majority of brain tumor patients22,23, recent 
scientific and translational advances have ignited a plethora of immunotherapy trials, particularly in 
GBM and brain metastases. To maximize enrollment to these studies and produce generalizable 
results24, several key eligibility criteria for immunotherapy trials must be carefully considered.  
 
First, a key consideration is the use of corticosteroids. Consistent with their immunosuppressive effect, 
recent data from preclinical GBM models25 as well as immunotherapy trials in GBM26 have suggested 
that corticosteroid use is associated with quantitative and qualitative T cell dysfunction and poorer 
outcomes. When possible, corticosteroids should therefore be avoided. However, despite their 
significant drawbacks, corticosteroids continue to play an essential role in the management of 
peritumoral edema and resultant symptoms in brain tumor patients.27  Although bevacizumab 
represents a potential alternative, it is expensive, associated with its own toxicity and risks, some of 
which can impact the timing of surgery, and may confound response assessment when administered 
with other antineoplastic therapies.28 Thus, some degree of corticosteroid use may be unavoidable in 
the majority of patients with aggressive brain tumors. Routine exclusion of patients requiring 
dexamethasone would severely limit eligibility for immunotherapy trials and lead to selection bias and 
less generalizable results. What the lowest dose of corticosteroids allowable for participation on an 
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immunotherapy trial should be depends on several factors including the patient population and the 
goals of the study. In patients with non-small lung cancer treated with programmed death (ligand) 1 
[PD-(L)1] blockade, baseline corticosteroid use of ≥ 10 mg/day of prednisone equivalent (i.e., 1.5 
mg/day dexamethasone) was associated with poorer outcome.29  For trials where efficacy is an 
important endpoint, a reasonable compromise would be to stratify patients to those who do not require 
corticosteroids, those who require modest dosing such as maximum total daily doses of 2 mg 
dexamethasone and, if deemed appropriate, those requiring higher doses. For early phase trials where 
toxicity is a primary endpoint, consensus opinion is to limit baseline dexamethasone dose to 2 mg/day 
or less as high doses of dexamethasone could mask toxicity from immunotherapy. Future studies of 
the dose relationship of corticosteroids to immune reactivity may help refine these guidelines and 
provide a better understanding of the duration of corticosteroid effects after successful cessation of 
treatment.  
 
Once a study participant has initiated immunotherapy treatment, steroid dosing could be liberalized to 
manage symptoms related to toxicity and/or cerebral edema. Data from the use of immunotherapies in 
systemic cancers suggest that implementation of short-term corticosteroids to manage immune-related 
adverse events (irAEs) does not seem to significantly alter efficacy.30,31 Laboratory based studies in 
GBM models suggest that, once anti-tumor immunity has been initiated, the negative impact of 
corticosteroids on immune function is markedly reduced.25 Pragmatically, for symptom management, 
patients able to start immunotherapy without corticosteroids may be able to use corticosteroids after 
immunotherapy has been implemented. The impact of this intervention also warrants careful 
prospective study.   
 
Second, given the key role of lymphocytes in mounting an anti-tumor immune response, cutoffs for 
minimum absolute lymphocyte counts (ALC) have been implemented in numerous immunotherapy 
trials. In GBM patients, however, lymphopenia is common, both at baseline due to sequestration of T 
cells in the bone marrow32 as well as due to corticosteroids and chemoradiation33. Although it is not 
yet known whether baseline ALC predicts immunotherapy outcomes in GBM, data from other cancers 
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has yielded mixed results. Some studies have demonstrated an association between baseline 
lymphopenia (ALC < 1000 cells/µL) and poor anti-tumor immune response and reduced immunologic 
toxicities34,35; others have failed to show such a relationship36. What baseline ALC value should be 
chosen as study entry criteria for immunotherapy trials is unclear and depends on the patient 
population and trial goals. In an ideal setting, when efficacy is a primary endpoint, baseline ALC > 
1000 cells/µL may be a reasonable cutoff. We recognize that this will make the study results less 
generalizable to the overall GBM population and could significantly limit study accrual. It can also be 
argued that, given the lack of clear data as well as a lack of proven efficacy of immunotherapy in 
primary brain tumors to date, it may be prudent to use a more liberal ALC cutoff, such as a minimum 
ALC of 500 cells/µL [i.e., NCI Common Terminology Criteria for Adverse Events (CTCAE) grade < 
3], until data from ongoing immunotherapy trials in brain tumors can determine if baseline ALC 
predicts response to immunotherapy.   
 
Finally, the presence of pre-existing autoimmune disease is a common exclusion criterion that may 
limit enrollment and generalizability in immune checkpoint inhibitor trials. Given that flares and irAEs 
in patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for non-small 
cell lung cancer (NSCLC) and melanoma are often manageable without discontinuing therapy37, as 
well as the dismal prognosis of GBM19, it is reasonable to allow patients with select, well-controlled, 
autoimmune diseases to enroll on GBM immune checkpoint inhibitor trials.  
 
GLIOBLASTOMA ELIGIBILITY CRITERIA  
Molecular Classification 
Advances in molecular diagnostics over the past decade have led to changes in the classification and 
grading of CNS tumors.38 A working group of the Consortium to Inform Molecular and Practical 
Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) made recommendations for a new 
integrated diagnosis for a subset of IDH-wildtype astrocytomas that exhibit an aggressive clinical 
course similar to GBM but do not meet histopathologic criteria for GBM.39,40 Based on expert opinion 
and an extensive literature review, cIMPACT-NOW established that histologic IDH-wildtype 
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astrocytomas of WHO grade II or III can be considered “Diffuse astrocytic glioma, IDH-wildtype, 
with molecular features of glioblastoma, WHO grade IV” if any one of the following is present41-45:  
high-level amplification of EGFR, whole chromosome 7 gain and whole chromosome 10 loss (+7/-
10), or TERT promoter mutation. Patients with tumors meeting these criteria should be considered 
eligible to participate in clinical trials for newly diagnosed or recurrent GBM.  
 
Another important change to glioma classification based on molecular profiling is the evolving 
definition of the term “secondary GBM”.  Traditionally, secondary GBM has referred to a GBM 
arising from a known grade II or III astrocytoma, proven by pathology.46 However, secondary GBMs 
may also now refer to a tumor that is histologically grade IV at initial diagnosis, but harbors an IDH1 
or IDH2 mutation, even without a known history of a lower grade astrocytoma.47 For IDH-mutant 
GBM, it may be reasonable to include these patients along with IDH-wildtype patients in Phase 0/I 
studies, where efficacy is not the primary endpoint. For Phase II/III trials with survival endpoints, 
however, stratification or exclusion based on IDH mutational status may be considered, as IDH-
mutant tumors have a distinct biology and may have a more indolent natural history.48,49 
 
Tumor-Treating Fields in Newly Diagnosed GBM Trials 
Tumor-treating fields (TTFields) is approved by the US FDA for use in combination with maintenance 
temozolomide in adults with newly diagnosed, supratentorial GBM following maximal debulking 
surgery and completion of radiation therapy. Discussions on approval and reimbursement are ongoing 
in many other countries worldwide. US approval, as well as its Category I recommendation status in 
the National Comprehensive Cancer Center (NCCN) guidelines for CNS Tumors, is based on the 
randomized, phase III EF-14 trial, which demonstrated survival benefit from the addition of TTFields 
to maintenance temozolomide chemotherapy.50 Despite this, a substantial proportion of patients with 
newly diagnosed GBM in the US do not use TTFields51, the reasons for which are not fully understood 
but may include the encumbrances related to carrying and maintaining the device. In other countries, 
there is large variation in access and request for this treatment.  
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The question of whether to allow use of TTFields in upfront GBM clinical trials needs to be addressed 
for each clinical trial. It is difficult to mandate the use of TTFields, especially for trials in countries 
where access and reimbursement is limited and especially when a substantial proportion of patients in 
the US chose not to use TTFields. On the other hand, routine exclusion of TTFields from front-line 
GBM trials in the US may impact enrollment from health care providers and patients motivated to use 
TTFields. More recently, the US NCI Brain Malignancies Steering Committee has advised against 
routine exclusion of TTFields, unless its use is harmful for participants on study.  
 
When and how TTFields should be incorporated into upfront GBM trials was heavily debated within 
the group. In general, the group did not favor mandating TTFields in trials. We discussed a variety of 
strategies for incorporating TTFields based on the clinical trial design and primary outcomes. In phase 
I studies, as long as TTFields is not considered harmful50,52 to combine with the experimental therapy, 
its use could be allowed with careful consideration of toxicity attribution to TTFields versus the 
experimental therapy. For single arm studies with efficacy endpoints, inconsistent use of TTFields 
across the study population may skew results and thereby limit the ability to isolate the treatment 
effect of the experimental therapy. For randomized trials in the newly diagnosed GBM setting, patients 
could theoretically be stratified by use of TTFields. Study teams would need to be aware of the 
additional logistical and statistical challenges with stratification by “intent to use TTFields” as most 
patients do not know at the time of randomization (for upfront studies, this could be at the time of 
initial surgery or before starting radiation) whether they would want to add TTFields to their post-
radiation treatment regimen. Lessons can be learned from the experience of “intent to use 
temozolomide” in a randomized phase III trial of standard of care with or without sitimagene 
ceradenovec in high grade glioma.53,54 During study proceedings, data emerged supporting the addition 
of temozolomide to radiotherapy and the protocol was amended to stratify according to intent to use 
temozolomide. However, non-adherence confounded the results; 24% of patients in both arms who 
had intended to use temozolomide did not use temozolomide on study.54  
 
Prior Treatments and Number of Relapses in Recurrent GBM Trials 
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Studies of hypofractionated radiation therapy in elderly adults with GBM55-57 and our increased 
understanding of the predictive value of MGMT promoter methylation on chemo-sensitivity58,59 have 
resulted in heterogeneous treatment approaches at diagnosis. Some patients may have received 
hypofractionated radiation (instead of standard 6-week radiation) and/or radiation without 
temozolomide at diagnosis or temozolomide alone without radiation, while others may have 
participated on an upfront clinical trial with experimental agents and/or radiation techniques. Limiting 
enrollment only to patients who received standard of care as upfront therapy excludes patients who 
may otherwise be reasonable trial candidates. In phase 0/I studies, exclusion of patients for alternative 
front-line therapy is generally not warranted. In general, recurrent GBM trials should not exclude 
based on prior treatment unless a particular study question or treatment related toxicity makes the prior 
treatment relevant. In phase II/III studies, where efficacy is an important endpoint, investigators 
should carefully consider (a) whether prior receipt of temozolomide or short-course radiation would 
realistically be expected to impact the efficacy of the investigational treatment (we would argue that in 
most cases, it would not) and (b) whether stratification rather than exclusion based on prior therapy 
received is warranted.  
 
A second major issue that limits trial eligibility in recurrent GBM is the exclusion of patients who are 
beyond first or second relapse. While the number of relapses may be relevant when considering 
efficacy endpoints60,61, this is much less important in phase 0/I studies (discussed further below). We 
recommend including all patients with recurrent GBM, irrespective of number of relapses, in early 
phase studies provided that the patient is otherwise an appropriate trial candidate in terms of 
performance status, expected survival, and co-morbidities.  
 
Overall survival (OS) is potentially influenced by whether a patient is in first versus second relapse. It 
is less clear whether PFS or RR would be influenced by first versus second relapse but could be 
influenced by prior therapies. For example, patients who experience disease progression while 
receiving bevacizumab rarely respond to further salvage therapy.62 Thus, for single arm phase II 
studies with a non-OS endpoint (i.e., PFS, RR), we recommend inclusion of patients in first or second 
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relapse. Instead of discriminating based on the number of relapses, studies may consider 
discriminating based on relevant prior therapies which would predict failure on trial. Randomized 
studies, including those with an OS endpoint, could stratify based on first versus second relapse. When 
efficacy is an important endpoint and there is a high likelihood that outcomes may be influenced by 
prior therapies, strategies to allow broader enrollment include specifying separate analyses for patients 
who have or have not received the particular treatment (e.g., bevacizumab refractory versus 
bevacizumab naïve), enrolling separate arms for these patient populations, or stratifying randomization 
based on prior exposure. 
 
ELIGIBLITY CRITERIA FOR PHASE I STUDIES 
Patients with primary CNS tumors are often excluded from first-in-human solid tumor clinical trials. 
Perceived poor prognosis and fear of excessive CNS toxicities are the major reasons for limiting 
access to early phase clinical trials63 but there is evidence to refute this perception. A pooled analysis 
of patients with recurrent WHO grade III and IV gliomas enrolled onto ABTC phase I trials compared 
findings with the published outcomes of patients with solid tumors enrolled onto phase I oncology 
trials of the same treatments. Patients with WHO grade III and IV gliomas who fulfilled the standard 
phase I eligibility criteria and were enrolled onto trials of appropriately chosen single-agent drugs 
successfully met phase I end points (namely safety, toxicity, and efficacy). The serious toxicities 
observed in these patients were within the acceptable toxicity rates seen in other solid tumor phase I 
trials. The maximum tolerated dose (MTD) was identical or marginally higher in WHO grade III and 
IV glioma patients who were not receiving enzyme-inducing anti-epileptic drugs (EIAEDs) compared 
with non-glioma patients or with glioma patients on EIAED.64 Therefore, one can argue that all Phase 
I clinical trials for solid tumors should allow enrollment of patients with WHO grade III or IV gliomas 
who otherwise meet the standard eligibility criteria, provided the investigational agent has adequate 
penetration across the blood-brain barrier or the mechanism of action does not require it to do so (e.g., 
certain immunotherapies). We also recommend addition of a specific expansion cohort for these 
tumors when there is a sound biologic rationale and favorable pharmacokinetic properties, including 
evidence of blood-brain barrier penetration as observed in preclinical models. Alternatively, expansion 
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cohorts can be designed in surgical patients who would receive experimental drug before tumor 
resection for clinical indications, and pharmacokinetic and pharmacodynamic data can be obtained on 
resected tumor tissue. These cohorts would help with making go-no-go decisions based on early 
outcomes data. 
 
In addition to patients with WHO grade III or IV gliomas, phase I trials may offer a way for patients 
with rare primary CNS tumors (e.g., diffuse midline gliomas, ependymomas, medulloblastomas) to 
obtain access to novel agents. These cancers have been less studied in the clinical research setting 
mainly due to their low incidence and slow accrual to clinical trials, as well as lack of incentive for 
pharmaceutical companies due to a small potential market. As with glioma patients, patients with rare 
CNS tumors can provide valuable data on safety and dose-finding in early phase clinical trials. In 
addition, one could potentially gain valuable efficacy signals that could then be evaluated further in 
expansion cohorts or in follow-up efficacy trials. This approach does offer opportunities for patients 
with rare diseases to participate but also underscores the need to mandate that the phase I efficacy data 
not be routinely be used as a go-no go decision for further investigation of the treatment agent or 
regimen. 
 
Restrictive eligibility criteria are also a significant barrier for patient accrual to clinical trials that are 
specifically designed for patients with primary brain tumors. The majority of early phase clinical trials 
in neuro-oncology are open only to patients with GBM. Other therapy restrictions such as the prior use 
of antiangiogenic drugs (typically bevacizumab) are also common, but not germane to the goals of 
phase I clinical trials. In addition, patients may be ineligible if their initial diagnosis was WHO grade 
II or grade III, even though they have pathologically proven GBM at the time of progression. Neither 
the number of prior recurrences nor lines of prior therapy nor pathologic grade (provided they meet 
criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO 
grade IV”) should exclude patients from phase I GBM trials so long as they meet other eligibility 
criteria required for enhancing the safety of clinical trials and completing the dose-limiting toxicity 
(DLT) period of observation. 
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Finally, many phase I clinical trials limit eligibility to patients with good Eastern Cooperative 
Oncology Group (ECOG) performance score of ≤ 1 or equivalent Karnofsky performance score (KPS) 
of ≥ 80.  The expected toxicity profile and mechanism of action of the investigational therapeutics 
should drive eligibility criteria in phase I trials, not a required functional status score. The primary 
brain tumor population specifically may experience neurologic deficits that do not directly affect their 
ability to tolerate treatments but limit their ability to self-care and thus lower their ECOG score to 2 or 
equivalent KPS to 60 (such as hemiparesis). Therefore, in selected phase I trials, primary brain tumor 
patients with lower performance scores (KPS ≥ 60) due to fixed deficits can be accrued without 
affecting the integrity of the study.   
 
OPTIMIZING PATIENT-RELATED FACTORS 
Patient accrual and retention are two critical obstacles to the successful completion of clinical trials. 
We currently live in an era of unprecedented connectivity, access to information and reliance on 
mobile technologies; these conditions may be exploited to improve the conduct of clinical trials for 
patients with brain tumors.  
 
Lack of awareness of available clinical trials is arguably the first barrier to improving patient accrual. 
A report from the Center for Information and Study on Clinical Research Participation found that most 
people (51%) would prefer to receive information on trials from their primary care physician or from 
study staff (44%).65 However, younger patients may rely on online resources or social media for 
information on trial options, and 84% of the adult population in the US use the internet.66 
CenterWatch, a resource for information on clinical trials, reported that 38% of patients find available 
studies through major search engines on the internet.67 Clearly, the potential for increasing 
dissemination of trial information using outreach and social media exists; the Collaborative 
Ependymoma Research Network Foundation (CERN) applied these strategies to form community-
academic partnerships to successfully accrue patients to ependymoma studies. Modern day 
technologies and mobile applications designed to aid clinicians and patients to browse available 
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clinical trials may boost awareness of appropriate studies and could also support platforms to recruit 
under-represented populations.  
 
Geographic access to clinical trials is another hurdle to both accrual and retention of patients. As Janet 
Woodcock, Director of the FDA’s Center for Drug Evaluation and Research (CDER), expressed “sites 
for clinical trials are frequently selected on the basis of where the investigators are located, as opposed 
to where the patients are, creating difficulties in patient recruitment”.68 A recent retrospective analysis 
of 1600 patients with cancer at a single center indicated that the overall median unidirectional distance 
traveled from home to study site was 25.8 miles, with patients enrolled on phase I studies having the 
longest travel (median of 41.2 miles).69 To offset the burden of travel, especially for patients with 
brain tumors who may have limited mobility, many routine clinical trial assessments such as blood 
work could be completed locally, with results provided to the study centers per a specified protocol. In 
addition, “remote” or “virtual” visits may be able to replace some clinical assessments. This 
telemedicine approach has successfully been implemented in other disease areas and has been shown 
to reduce costs and improve care for patients with neuro-degenerative conditions that impair mobility 
and travel to clinical centers.70 Moreover, the use of wearable devices to gather patient specific 
information could facilitate data collection of functional outcomes. Two recent large, randomized 
studies (ClinicalTrials.gov Identifiers: NCT02511405 and NCT02152982) conducted in patients with 
GBM completed accrual much sooner than expected; it is possible that these successes were as a result 
of allowing administration of backbone therapies (i.e., radiation therapy, bevacizumab) to be delivered 
locally in the community. Finally, use of a central institutional review board (IRB) for multicenter 
trials could circumvent the need for cumbersome local IRB approval requirement that can hinder 
patient enrollment. All these novel approaches require changes in how institutions and methods for 
data collection are sanctioned as acceptable for use in clinical trials. 
 
Another impediment to clinical trial accrual and retention may be the lack of patient focused 
approaches. Study designers do not generally consider the patient experience in writing clinical trials, 
as most efforts are focused on evaluating the efficacy and safety of an intervention and often 
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maximizing the amount of data collected. However, patients are the key “customers” for clinical trials 
and hence their perspective is crucial to capturing and maintaining their participation. A recent survey 
indicated that patient involvement in trial design early on, including selection of outcomes and 
measurement tools, is recommended to improve the completion rate of trials for rare diseases.71 This is 
in keeping with the recent emphasis on “patient-focused drug development” that takes into 
consideration patients’ priorities. To gather stakeholder input, Leiter et al. instituted an internet 
crowdsourcing platform to collect feedback from clinicians, patients, and advocates that led to 
significant modifications to an oncology trial. They found that crowdsourcing participation in clinical 
trial design was not only feasible, but worthwhile.72 
 
CONCLUSIONS 
Building on work by Friends/ASCO, FDA, and NCI in optimizing eligibility criteria for oncology 
trials, we provide additional recommendations regarding eligibility criteria and the conduct of neuro-
oncology trials involving primary brain tumors. It is also important to consider the trial design or 
phase of development. As long as known safety data about a study agent is taken into account, 
eligibility criteria for phase I trials should be more permissive, particularly with respect to histology 
and grade. For randomized, phase III trials aimed at assessing definitive therapeutic benefit, patients 
can be stratified according to key characteristics such as number of prior relapses or IDH mutation 
status to allow greater inclusion. 
 
This discussion also provides an introduction to some of the strategies that may transform clinical trial 
conduct for patients with brain tumors. There are multiple opportunities to exploit existing 
technologies and information networks to improve access to clinical trials for both patients and 
providers. However, as with any proposal to include novel approaches, introducing these changes will 
come with challenges. For example, the practical and regulatory framework for many of these 
applications are unclear. Who will pay for local testing and telemedicine visits? Will community 
physicians be responsible for following up with clinical trial laboratory results? Where do referring 
physicians and community oncologists fit in the clinical trial structure? How do we prioritize fostering 
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awareness, outreach and education for all stakeholders? Despite these uncertainties, it is imperative 
that we as a community move forward to address these issues, endeavor to overcome resistance to 
change, and work toward optimizing the conduct of clinical trials for our patients. 
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FIGURE LEGEND 
Figure 1: Reasons for ineligibility at screening for 153 patients with newly diagnosed or recurrent 
glioblastoma who signed consent for one of six PI-initiated clinical trials at Dana-Farber Cancer 
Institute between 3/2009 and 2/2019.  
 
 
